Affiliation:
1. IBSAL‐University Hospital of Salamanca Salamanca Spain
2. Department of Medicine University of Salamanca Salamanca Spain
3. RICORS TERAV ISCIII Madrid Spain
4. Regenerative Medicine and Cellular Therapy Network Center of Castilla y León Salamanca Spain
5. Department of Surgery University of Salamanca Salamanca Spain
Abstract
AbstractBackgroundDespite notable advances in the support and treatment of patients admitted to the intensive care unit (ICU), the management of those who develop a systemic inflammatory response syndrome (SIRS) still constitutes an unmet medical need.Main bodyBoth the initial injury (trauma, pancreatitis, infections) and the derived uncontrolled response promote a hyperinflammatory status that leads to systemic hypotension, tissue hypoperfusion and multiple organ failure. Mesenchymal stromal/stem cells (MSCs) are emerging as a potential therapy for severe ICU patients due to their potent immunomodulatory, anti‐inflammatory, regenerative and systemic homeostasis‐regulating properties. MSCs have demonstrated clinical benefits in several inflammatory‐based diseases, but their role in SIRS needs to be further explored.ConclusionIn the current review, after briefly overviewing SIRS physiopathology, we explore the potential mechanisms why MSC therapy could aid in the recovery of this condition and the pre‐clinical and early clinical evidence generated to date.
Subject
Molecular Medicine,Medicine (miscellaneous)
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献